Related Experiment Video

Updated: May 18, 2026

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

Heart defects treatment in Sergipe: propose of resources' rationalization to improve care

Debora Cristina Fontes Leite1, José Teles de Mendonça, Rosana Cipolotti

  • 1Federal University of Sergipe, Santa Isabel Maternity Neonatal Intensive Care Unit, Aracaju, Brazil. deboraleite2006@hotmail.com

Revista Brasileira De Cirurgia Cardiovascular : Orgao Oficial Da Sociedade Brasileira De Cirurgia Cardiovascular
|September 22, 2012
PubMed

Insights

Surgical correction of congenital heart disease in Sergipe, Brazil, showed a decrease in surgical deficit from 69% to 55.3%. Centralization of resources is recommended to improve congenital heart defect treatment outcomes.

Area of Science:

  • Pediatric Cardiology
  • Cardiac Surgery
  • Public Health

Background:

  • Congenital heart disease (CHD) requires timely surgical intervention.
  • Evaluating surgical treatment patterns and outcomes is crucial for improving patient care.
  • The study period covers 2000-2009 in Sergipe, Brazil.

Purpose of the Study:

  • To evaluate the surgical treatment of congenital heart disease.
  • To analyze trends and outcomes over a ten-year period.
  • To assess the impact of surgical centralization on CHD treatment.

Main Methods:

  • Retrospective analysis of all patients undergoing surgical correction for CHD.
  • Data collected from three hospitals in Aracaju, Sergipe, Brazil.
  • Analysis included patient demographics, diagnoses, procedures, and the RACHS-1 (Risk Adjustment in Congenital Heart Surgery) score.

Main Results:

  • Surgical deficit decreased from 69% in Period I to 55.3% in Period II.
  • Common diagnoses included interventricular communication (20.5%), patent ductus arteriosus (20.2%), and atrial septal defect (19%).
  • The RACHS-1 score demonstrated a statistically significant correlation with observed hospital mortality (AUC = 0.860).

Conclusions:

  • Centralization and organization of resources are necessary for improving surgical correction of CHD.
  • The RACHS-1 score is a reliable predictor of hospital mortality in pediatric cardiac surgery.
  • Findings highlight the need for improved healthcare system organization for CHD treatment.
Abstract

More Related Videos

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine05:36

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...